Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lentzsch, S.
Right arrow Articles by D’Amato, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lentzsch, S.
Right arrow Articles by D’Amato, R. J.
[Cancer Research 62, 2300-2305, April 15, 2002]
© 2002 American Association for Cancer Research

Experimental Therapeutics

S-3-Amino-phthalimido-glutarimide Inhibits Angiogenesis and Growth of B-Cell Neoplasias in Mice1

Suzanne Lentzsch2, Michael S. Rogers2, Richard LeBlanc, Amy E. Birsner, Jamshed H. Shah, Anthony M. Treston, Kenneth C. Anderson and Robert J. D’Amato3

Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115 [S. L., R. L., K. C. A.]; Department of Surgery, Children’s Hospital, and Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts 02115 [M. S. R., A. E. B., R. J. D.]; and EntreMed Inc., Rockville, Maryland 20850 [J. H. S., A. M. T.]

Thalidomide has recently been shown to be useful in the treatment of multiplemyeloma and may also be useful in the treatment of other hematological malignancies.We have identified a new derivative of thalidomide, S-3-[3-amino-phthalimido]-glutarimide (S-3APG) with dual activity against B-cell neoplasias. S-3APG was able to directly inhibit the proliferation of myeloma and Burkitt’s lymphoma cell lines in vitro without showing toxicity to normal bone marrow stromal cells or hematopoietic progenitor cells. In vivo, S-3APG treatment of drug resistant myeloma cell tumors in mice was able to produce complete and sustained regressions without any observed toxicity. Additionally, S-3APG induced complete regressions of Burkitt’s lymphoma cell tumors. Furthermore, S-3APG inhibited angiogenesis more potently than thalidomide in the murine corneal micropocket model. We conclude that S-3APG is a powerful anti-myeloma and anti-B-cell-lymphoma agent that has both antiproliferative and antiangiogenic effects.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
R. Feng, H. Ma, C. A. Hassig, J. E. Payne, N. D. Smith, M. Y. Mapara, J. H. Hager, and S. Lentzsch
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling
Mol. Cancer Ther., June 1, 2008; 7(6): 1494 - 1505.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. Anderson, M. Gries, N. Kurihara, T. Honjo, J. Anderson, V. Donnenberg, A. Donnenberg, I. Ghobrial, M. Y. Mapara, D. Stirling, et al.
Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1
Blood, April 15, 2006; 107(8): 3098 - 3105.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Hideshima, D. Chauhan, P. Richardson, and K. C. Anderson
Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma
J. Clin. Oncol., September 10, 2005; 23(26): 6345 - 6350.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K.-R. Koh, M. Janz, M. Y. Mapara, B. Lemke, D. Stirling, B. Dorken, M. Zenke, and S. Lentzsch
Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis
Blood, May 15, 2005; 105(10): 3833 - 3840.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. S. W. Ng, G. R. MacPherson, M. Gutschow, K. Eger, and W. D. Figg
Antitumor Effects of Thalidomide Analogs in Human Prostate Cancer Xenografts Implanted in Immunodeficient Mice
Clin. Cancer Res., June 15, 2004; 10(12): 4192 - 4197.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
J Bauditz, G Schachschal, S Wedel, and H Lochs
Thalidomide for treatment of severe intestinal bleeding
Gut, April 1, 2004; 53(4): 609 - 612.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Hideshima, M. Akiyama, T. Hayashi, P. Richardson, R. Schlossman, D. Chauhan, and K. C. Anderson
Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu
Blood, January 15, 2003; 101(2): 703 - 705.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. LeBlanc, L. P. Catley, T. Hideshima, S. Lentzsch, C. S. Mitsiades, N. Mitsiades, D. Neuberg, O. Goloubeva, C. S. Pien, J. Adams, et al.
Proteasome Inhibitor PS-341 Inhibits Human Myeloma Cell Growth in Vivo and Prolongs Survival in a Murine Model
Cancer Res., September 1, 2002; 62(17): 4996 - 5000.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
K. C. Anderson, J. D. Shaughnessy Jr., B. Barlogie, J.-L. Harousseau, and G. D. Roodman
Multiple Myeloma
Hematology, January 1, 2002; 2002(1): 214 - 240.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.